Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H27N3O6 |
| Molecular Weight | 393.4342 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C3CCCCC3)C1=O
InChI
InChIKey=RUEYEZADQJCKGV-UHFFFAOYSA-N
InChI=1S/C19H27N3O6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,15H,1-11H2,(H,20,25)(H,23,24)
| Molecular Formula | C19H27N3O6 |
| Molecular Weight | 393.4342 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Daprodustat (DUVROQ) is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (PHD) developed by GlaxoSmithKline for the treatment of anaemia in patients with chronic kidney disease (CKD). Inhibition of PHD prevents degradation of hypoxia-inducible factor (HIF), leading to the production of erythropoietin and subsequent induction of erythropoiesis. In June, daprodustat received its first approval in Japan for the treatment of renal anaemia.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3028 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28928122 |
3.5 nM [IC50] | ||
Target ID: CHEMBL5697 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28928122 |
22.2 nM [IC50] | ||
Target ID: CHEMBL5705 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28928122 |
5.5 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | JESDUVROQ Approved UseJESDUVROQ is a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least four months Launch Date2023 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
140 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31619187 |
10 mg 3 times / week steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DAPRODUSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
247 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31619187 |
25 mg 3 times / week steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DAPRODUSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
387 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31619187 |
30 mg 3 times / week steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DAPRODUSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
348 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31619187 |
10 mg 3 times / week steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DAPRODUSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1214 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31619187 |
25 mg 3 times / week steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DAPRODUSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1369 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31619187 |
30 mg 3 times / week steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DAPRODUSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.1 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31619187 |
10 mg 3 times / week steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DAPRODUSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31619187 |
25 mg 3 times / week steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DAPRODUSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31619187 |
30 mg 3 times / week steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DAPRODUSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 71.0 |
no | |||
Sources: https://www.pmda.go.jp/drugs/2020/P20200619003/340278000_30200AMX00505_I100_1.pdf#page=53 Page: 53.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Sources: https://www.pmda.go.jp/drugs/2020/P20200619003/340278000_30200AMX00505_I100_1.pdf#page=53 Page: 53.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Sources: https://www.pmda.go.jp/drugs/2020/P20200619003/340278000_30200AMX00505_I100_1.pdf#page=53 Page: 53.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 70.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
yes [IC50 11 uM] | |||
Page: 70.0 |
yes [IC50 21 uM] | |||
Page: 71.0 |
yes [IC50 6 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 71.0 |
major | yes (co-administration study) Comment: Gemfibrozil increased Cmax and AUCinf by 3.9-fold and 18.6-fold. Page: 71.0 |
||
Page: 71.0 |
minor | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
no | |||
Page: 71.0 |
weak | |||
Page: 71.0 |
weak | |||
Page: 71.0 |
yes | |||
Page: 71.0 |
yes | |||
Page: 71.0 |
yes | |||
Page: 71.0 |
yes | |||
Page: 71.0 |
yes | |||
Page: 71.0 |
yes |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28928122
Human CP4H/Cofactor mix (4X final concentration in 50 mM HEPES, pH 7.5 with 50 mM KCl) was incubated at room temperature for 30 minutes with GSK1278863 (10 point, 3-fold serial dilution in 50% DMSO, 15X final concentration) or 50% DMSO. Substrate mix (1.4X final concentration in 50 mM HEPES, pH 7.5 with 50 mM KCl) was added to the plate yielding a 32 μL final reaction volume. After 20 minutes, the reaction was quenched by the addition of 0.67% final H3PO4. Product formation was detected using Reverse Phase High Performance Liquid Chromatography (HPLC; Ex 336nM and Em 517 nM). Final concentrations of the CP4H/Cofactor mix were 21.11 nM enzyme, 1 mg/mL BSA, 50 μM FeCl2, 2 mM ascorbic acid, 100 μM DTT, and 100 μg/mL catalase. The substrate mix consisted of 100 μM dansyl-GFPG-Oet, and 110 μM α-ketoglutarate. Percent inhibition data were determined from the ratio of product to substrate after a 20 minute reaction. The IC50 value was determined by fitting the percent inhibition data to a two-parameter IC50 equation.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:31:48 GMT 2025
by
admin
on
Wed Apr 02 08:31:48 GMT 2025
|
| Record UNII |
JVR38ZM64B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Daprodustat
Created by
admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
|
PRIMARY | |||
|
JVR38ZM64B
Created by
admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
|
PRIMARY | |||
|
DB11682
Created by
admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
|
PRIMARY | |||
|
JVR38ZM64B
Created by
admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
|
PRIMARY | |||
|
DTXSID501337360
Created by
admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
|
PRIMARY | |||
|
SUB185070
Created by
admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
|
PRIMARY | |||
|
BC-163
Created by
admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
|
PRIMARY | |||
|
91617630
Created by
admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
|
PRIMARY | |||
|
10167
Created by
admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
|
PRIMARY | |||
|
C169877
Created by
admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
|
PRIMARY | |||
|
960539-70-2
Created by
admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
|
PRIMARY | |||
|
CHEMBL3544988
Created by
admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
|
PRIMARY | |||
|
100000170880
Created by
admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|